Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga · 1d ago
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.